Catalyst Dossier · compiled by CeliA 🧫

Vaccinex, Inc. (VCNX)

Pharmaceutical Preparations · market cap $3M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Avelumab and Pepinemab	Phase 2	Metastatic Pancreatic Adenocarcinoma
VX15/2503 + avelumab	Phase 2	Carcinoma, Non-Small-Cell Lung
pepinemab + pembrolizumab	Phase 2	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
VX15/2503	Phase 2	Huntington's Disease
Pepinemab	Phase 2	Alzheimer Disease
2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)	Phase 3	Human Papillomavirus (HPV) Infection
SARS-CoV-2 (LVRNA009) 50μg group	Phase 2	SARS-CoV-2
Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)	Phase 2	HPV Infection
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)	Phase 2	COVID-19
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)	Phase 3	HPV InfectioN
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)	Phase 3	Norovirus Infections

Price & technical context

3-month

-20.6%

6-month

-37.5%

12-month

-86.8%

52-wk range

$0.34–$4.05

vs 50-day MA

-20.9%

vs 200-day MA

-31.6%

Realized vol

279.5%

Max drawdown

-96.1%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VCNX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.